Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Inclusion Criteria: * Histologically confirmed invasive thymoma or thymic carcinoma, meeting the following criteria: * Relapsed or refractory disease * Metastatic, unresectable disease * Locally invasive disease allowed provided it is not resectable and has been previously treated * Progressive disease * Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques or \>= 10 mm by spiral CT scan * Must have received \>= 1 prior chemotherapy regimen * No active brain metastases * Patients with previously treated brain metastases (surgical resection or radiotherapy) are eligible provided they have documented stable brain disease for \>= 1 month after completion of therapy and are asymptomatic * ECOG performance status 0-2 * Leukocytes \>= 3,000/mm\^3 * ANC \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Hemoglobin \> 9 g/dL * Serum bilirubin \< 2.0 times upper limit of normal (ULN) * Transaminases =\< 2.5 times ULN (\< 5.0 times ULN if liver metastasis is present) * Serum creatinine \< 1.5 times ULN OR creatinine clearance \> 50 mL/min * Urine protein:creatinine ratio \< 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection * QTc \< 460 msec * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 30 days after completion of study treatment * No known history of allergic reactions attributed to compounds of similar chemical or biological composition…